Treatment of respiratory syncytial virus with palivizumab: a systematic review
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pediatrics, Perinatology, and Child Health
Link
http://link.springer.com/content/pdf/10.1007/s12519-010-0230-z.pdf
Reference22 articles.
1. Whimbey E, Englund JA, Couch RB. Community respiratory virus infections in immunocompromised patients with cancer. Am J Med 1997;102(3A):10–18; discussion 25–26.
2. Robinson RF. Impact of respiratory syncytial virus in the United States. Am J Health Syst Pharm 2008;65(23 Suppl 8):S3–S6.
3. Committee on Infectious Diseases. From the American Academy of Pediatrics: policy statements—Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009;124: 1694–1701.
4. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531–537.
5. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532–540.
Cited by 39 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Efficacy and Safety of Palivizumab as a Prophylaxis for Respiratory Syncytial Virus (RSV) Disease: An Updated Systemic Review and Meta-Analysis;Cureus;2023-12-31
2. Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection;Cochrane Database of Systematic Reviews;2023-10-23
3. A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virus;Proceedings of the National Academy of Sciences;2023-08-17
4. Antiviral neutralizing antibodies: from in vitro to in vivo activity;Nature Reviews Immunology;2023-04-17
5. The mechanism and pharmacodynamics of 2-((1H-indol-3-yl)thio/sulfinyl)-N-pheny acetamide derivative as a novel inhibitor against human respiratory syncytial virus;Journal of Enzyme Inhibition and Medicinal Chemistry;2022-09-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3